Ischemia-Modified Albumin May Be a Novel Marker for Predicting Neonatal Neurologic Injury in Small-For-Gestational-Age Infants in Addition to Neuron-Specific Enolase

Tayman, Cüneyt; Öztekin, Osman; Serkant, Utku; Yakut, Ibrahim; Aydemir, Salih; Köşüş, Aydın

doi:10.1055/s-0036-1588026

Cited by 5 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study of Tayman et al, 21 the mean IMA value of appropriate for gestational age (AGA) babies was higher in the study group than that of the control group. In our study, the absorbance method was used as the measurement method, and the preoperative mean IMA values of babies with congenital heart disease in our study were still lower than AGA babies of the mentioned study.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Ischemic-Modified Albumin in Neonates with Congenital Heart Defects

et al. 2022

View full text Add to dashboard Cite

Objectives Ischemia-modified albumin (IMA) is a new biochemical marker of ischemia. We aimed to search blood IMA levels in neonates with congenital heart defects. Study Design During the study period, patients diagnosed with congenital heart disease and newborns with a diagnosis of hyperbilirubinemia as a control group were included in the study. IMA level was analyzed using the IMA absorbance unit (ABSU) method. Results In total, 57 newborns with congenital heart disease requiring cardiac operation for the study group and 38 newborns for the control group were included. There was no difference between the two groups in terms of gender, mode of delivery, and weeks of gestation. The average IMA values in the control group were 0.19 ± 0.09 ABSU. The prepostoperative mean IMA values of the patient group were 0.22 ± 0.07 and 0.23 ± 0.07 ABSU, respectively. Comparison of the postoperative IMA with the mean of the control group was statistically significant. Preoperative and postoperative IMA values of patients who have died due to primary heart disease and surgical complications were 0.21 ± 0.07 (0.08–0.32) ABSU and 0.25 ± 0.06 (0.12–0.36) ABSU, respectively. IMA levels were not statistically different between the two groups. Conclusion Hypoxia and ischemia in congenital heart disease in the newborn period both preoperatively and postoperatively were important in prognosis. IMA was higher in the postoperative group. Many comprehensive studies are important in terms of preventing complications and decreasing mortality and morbidity by commenting on prognosis. Key Points

show abstract

Section: Discussionmentioning

confidence: 92%

“…There are literature studies commenting on the relationship of IMA with hypoxia and ischemia, transient neonatal tachypnea, intrauterine growth retardation, respiratory distress syndrome, and low birth weight babies. [8][9][10][19][20][21] However, there is no study investigating the relationship between congenital heart defects and IMA.…”

Section: Discussionmentioning

confidence: 99%

Ischemic-Modified Albumin in Neonates with Congenital Heart Defects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These would have also been excluded for other reasons such as not meeting FGR definition (very low birth weight, preterm birth only), not assessing neurodevelopmental outcomes, or that no blood biomarkers were assessed. One study was excluded as it did not include neurodevelopmental assessments (36) and another was excluded as it reported only the presence of brain injury for the FGR cohort (37). Finally, one study was a twin study but was excluded as it did not separate the FGR twins from the normally grown pair for comparison (38).…”

Section: Resultsmentioning

confidence: 99%

“…Small for gestational age (SGA) differs from FGR in that it is solely defined by birthweight <10th percentile (3)(4)(5). We observed, however, that the studies included for full text review that included SGA cohorts either did not have a cohort of NG infants as controls or did not conduct a neurodevelopmental assessment >12 months of age for the NG cohort (31)(32)(33)(34)(35)(36)(37). Therefore, even when broadening the inclusion criteria to include SGA infants, our search of the current literature still only yielded one study that met all inclusion criteria.…”

Section: Resultsmentioning

confidence: 99%

The search for blood biomarkers that indicate risk of adverse neurodevelopmental outcomes in fetal growth restriction

Musco,

Beecher,

Chand

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Fetal growth restriction (FGR) impacts 5%–10% of pregnancies and is associated with increased risk of mortality and morbidity. Although adverse neurodevelopmental outcomes are observed in up to 50% of FGR infants, a diagnosis of FGR does not indicate the level of risk for an individual infant and these infants are not routinely followed up to assess neurodevelopmental outcomes. Identifying FGR infants at increased risk of adverse neurodevelopmental outcomes would greatly assist in providing appropriate support and interventions earlier, resulting in improved outcomes. However, current methods to detect brain injury around the time of birth lack the sensitivity required to detect the more subtle alterations associated with FGR. Blood biomarkers have this potential. This systematic review assessed the current literature on blood biomarkers for identifying FGR infants at increased risk of adverse neurodevelopmental outcomes at >12 months after birth. Four databases were searched from inception to 22 February 2024. Articles were assessed for meeting the inclusion criteria by two reviewers. The quality of the included article was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. A summary of findings is presented as insufficient articles were identified for meta-analysis. Excluding duplicates, 1,368 records were screened with only 9 articles considered for full text review. Only one article met all the inclusion criteria. Quality assessment indicated low risk of bias. Both blood biomarkers investigated in this study, neuron specific enolase and S100B, demonstrated inverse relationships with neurodevelopmental assessments at 2 years. Four studies did not meet all the inclusion criteria yet identified promising findings for metabolites and cytokines which are discussed here. These findings support the need for further research and highlight the potential for blood biomarkers to predict adverse outcomes.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=369242, Identifier CRD42022369242.

show abstract

“…While Mazarico et al [52] observed significantly higher levels of NSE in fetal umbilical arterial and maternal blood at birth in FGR, other studies have not observed this alteration [54, 58]. Tayman et al [59] observed increased NSE levels in peripheral venous blood 12 h after birth for SGA compared to AGA neonates; however, levels were decreased in asymmetric SGA compared to symmetric SGA neonates.…”

Section: Potential Biomarkers Of Interestmentioning

confidence: 99%

Blood Biomarkers in the Fetally Growth Restricted and Small for Gestational Age Neonate: Associations with Brain Injury

Musco¹,

Beecher²,

Chand³

et al. 2023

Dev Neurosci

View full text Add to dashboard Cite

Fetal growth restriction (FGR) and small for gestational age (SGA) infants have increased risk of mortality and morbidity. Although both FGR and SGA infants have low birthweights for gestational age, a diagnosis of FGR also requires assessments of umbilical artery Doppler, physiological determinants, neonatal features of malnutrition, and in utero growth retardation. Both FGR and SGA are associated with adverse neurodevelopmental outcomes ranging from learning and behavioral difficulties to cerebral palsy. Up to 50% of FGR, newborns are not diagnosed until around the time of birth, yet this diagnosis lacks further indication of the risk of brain injury or adverse neurodevelopmental outcomes. Blood biomarkers may be a promising tool. Defining blood biomarkers indicating an infant’s risk of brain injury would provide the opportunity for early detection and therefore earlier support. The aim of this review was to summarize the current literature to assist in guiding the future direction for the early detection of adverse brain outcomes in FGR and SGA neonates. The studies investigated potential diagnostic blood biomarkers from cord and neonatal blood or serum from FGR and SGA human neonates. Results were often conflicting with heterogeneity common in the biomarkers examined, timepoints, gestational age, and definitions of FGR and SGA used. Due to these variations, it was difficult to draw strong conclusions from the results. The search for blood biomarkers of brain injury in FGR and SGA neonates should continue as early detection and intervention is critical to improve outcomes for these neonates.

show abstract

Ischemia-Modified Albumin May Be a Novel Marker for Predicting Neonatal Neurologic Injury in Small-For-Gestational-Age Infants in Addition to Neuron-Specific Enolase

Cited by 5 publications

References 40 publications

Ischemic-Modified Albumin in Neonates with Congenital Heart Defects

Ischemic-Modified Albumin in Neonates with Congenital Heart Defects

The search for blood biomarkers that indicate risk of adverse neurodevelopmental outcomes in fetal growth restriction

Blood Biomarkers in the Fetally Growth Restricted and Small for Gestational Age Neonate: Associations with Brain Injury

Contact Info

Product

Resources

About